@article {8201,
	title = {Primary therapy of multiple myeloma with paclitaxel (taxol)},
	journal = {Annals of Oncology},
	volume = {5},
	year = {1994},
	note = {Cited By :18Export Date: 21 February 2017},
	month = {1994},
	pages = {757 - 759},
	abstract = {Background: The treatment of multiple myeloma remains unsatisfactory and new active agents are needed. Paclitaxel is effective against a variety of solid tumors and we assessed the utility against multiple myeloma. Patients and methods: From March 1993 to May 1994, we treated 33 patients with newly diagnosed multiple myeloma with paclitaxel given intravenously at a dose of 125 mg/m2 over 24 hours (13 patients) or at a dose of 135 mg/m2 over 3 hours (20 patients). Results: Five of 33 patients responded (15\%; 95\% CI: 5 to 32\%) with an unmaintained remission of 3-11+ months. Severe but reversible neutropenia was the major dose limiting toxicity, but myalgias and alopecia were also common. Conclusions: Paclitaxel was slightly active against multiple myeloma. Whether higher doses or new analogues of this agent can produce superior results requires further study. {\textcopyright} 1994 Kluwer Academic Publishers.},
	keywords = {multiple myeloma, Paclitaxel},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0028064597\&partnerID=40\&md5=f796674e1e73f4ae86feb6ad469cb05f},
	author = {Dimopoulos, M.A. and Arbuck, S. and Huber, M. and Weber, D. and Luckett, R. and Delasalle, K. and Alexanian, R.}
}
